Tianyu Group: The Active Pharmaceutical Ingredient Irbesartan Obtained the CEP Certificate.

Tianyu Corporation announces that the company has received the European Pharmacopoeia certification for the European Pharmacopoeia suitability of the active pharmaceutical ingredient of Eprosartan. Eprosartan is a type of antihypertensive medication used to treat primary hypertension and diabetic nephropathy associated with type 2 diabetes and hypertension. The company submitted a drug registration application in December 2024 and obtained a Certificate of Suitability (CEP). The certificate number is CEP 2025-025 - Rev 00, valid for five years from May 15, 2025. Currently, the company has a total of 2 CEP certificates for Eprosartan, bringing positive effects for further expanding into international markets.